As two N-terminally cleaved forms of IL-38 with an increased inhibitory activity have been identified in tumor cells44, we hypothesize that IL-38 is processed in our in vivo experimental system, likely owing to extracellular neutrophil proteases abundantly released in the IMQ-treated skin31,45,46. This evidence concerns the gene IL1F10 and neoplasm.